There is no cure yet, but now, a newly FDA-approved drug is helping to slow its progression before it’s too late.
Alzheimer’s drug Leqembi has full FDA approval THE ASSOCIATED PRESS July 7, 2023 at 07:30 JST Share Tweet list Print This image provided by Eisai in January 2023 shows vials and packaging for ...
WASHINGTON--Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated ...
Biogen is set for a revenue boost thanks to the approval of Alzheimers drug Leqembi. But other companies will also benefit ...
Vigil Neuroscience (NASDAQ:VIGL) said the FDA is allowing a Phase 1 clinical trial for its Alzheimer’s drug candidate VG-3927 to proceed with a partial clinical hold related to the maximum drug ...
The FDA also gave full approval to a drug called Leqembi, which slowed Alzheimer’s patients’ functional and cognitive decline by 27% over 18 months, according to trial data.
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.
A potential new Alzheimer’s drug represses the harmful inflammatory response of the brain’s immune cells, reducing disease ...
Sep. 18, 2023 — Is it possible that a single biomarker can detect all types of diseases related to dopamine deficiency in the brain? Yes, that's what a research group is discovering. 'We have ...
An advisory committee to the U.S. Food and Drug Administration unanimously rejected a drug-and-device combination made by a Boston biotech, which the agency had already rejected twice.
We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...
Valene Campbell started to have a sinking feeling as she was standing in the security line at the airport. It was fall 2016, and she was headed to London for a birthday celebration. But Campbell ...
